Clinical Trial Update: A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating tilosotolimod with ipilimumab versus ipilimumab alone in anti-PD-1 refractory metastatic melanoma was terminated; results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)
• tilsotolimod (tilsotolimod)

Snippet

Sponsor: Idera Pharmaceuticals, Inc. | Conditions: Metastatic Melanoma | Phase 3 | Status: TERMINATED | Results posted: 2022-11-08